| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 技术服务(元) | 14,067,947.27 | 17,076,894.39 | 11,785,975.15 | - | 6,553,304.63 |
| 重组蛋白(元) | 401,543,959.30 | 678,962,411.44 | 318,690,893.45 | 535,693,555.35 | 253,511,999.78 |
| 抗体、试剂盒及其他试剂(元) | 75,322,092.59 | 127,519,228.34 | 49,908,935.53 | 79,794,364.09 | 33,794,896.27 |
| 检测服务(元) | - | - | - | 17,448,458.51 | - |
| 营业成本(元) | |||||
| 技术服务(元) | 2,417,202.75 | 3,752,461.75 | 2,907,324.33 | - | 1,649,778.92 |
| 重组蛋白(元) | 35,536,640.40 | 46,856,832.89 | 28,363,489.52 | 39,002,496.56 | 13,917,808.79 |
| 抗体、试剂盒及其他试剂(元) | 6,944,696.94 | 14,193,781.89 | 4,611,914.98 | 8,229,012.44 | 2,557,876.67 |
| 检测服务(元) | - | - | - | 2,137,551.18 | - |
| 毛利(元) | |||||
| 技术服务(元) | 11,650,744.52 | 13,324,432.64 | 8,878,650.82 | - | 4,903,525.71 |
| 重组蛋白(元) | 366,007,318.90 | 632,105,578.55 | 290,327,403.93 | 496,691,058.79 | 239,594,190.99 |
| 抗体、试剂盒及其他试剂(元) | 68,377,395.65 | 113,325,446.45 | 45,297,020.55 | 71,565,351.65 | 31,237,019.60 |
| 检测服务(元) | - | - | - | 15,310,907.33 | - |
| 毛利率(%) | |||||
| 技术服务(%) | 82.82 | 78.03 | 75.33 | - | 74.83 |
| 重组蛋白(%) | 91.15 | 93.10 | 91.10 | 92.72 | 94.51 |
| 抗体、试剂盒及其他试剂(%) | 90.78 | 88.87 | 90.76 | 89.69 | 92.43 |
| 检测服务(%) | - | - | - | 87.75 | - |
| 收入构成(%) | |||||
| 技术服务(%) | 2.87 | 2.07 | 3.10 | - | 2.23 |
| 重组蛋白(%) | 81.79 | 82.44 | 83.78 | 84.64 | 86.27 |
| 抗体、试剂盒及其他试剂(%) | 15.34 | 15.48 | 13.12 | 12.61 | 11.50 |
| 检测服务(%) | - | - | - | 2.76 | - |
| 毛利构成(%) | |||||
| 技术服务(%) | 2.61 | 1.76 | 2.58 | - | 1.78 |
| 重组蛋白(%) | 82.06 | 83.31 | 84.27 | 85.11 | 86.89 |
| 抗体、试剂盒及其他试剂(%) | 15.33 | 14.94 | 13.15 | 12.26 | 11.33 |
| 检测服务(%) | - | - | - | 2.62 | - |